Syncro Group har publicerat bolagets delårsrapport för det tredje kvartalet 2023, såväl som att konc...
Redeye states that following a long streak of dissatisfactory sales, Neonode is now clearly re-direc...
Redeye updates its estimates following Surgical Science’s Q3 2023 report, which featured considerabl...
Revenues and EBIT of Danish operations growth by 23% and 89% Delays meant that order intake dropped ...
VBG Group levererar ytterligare ett starkt kvartal.
Redeye has opened an Analyst Q&A in conjunction with the latest research update on Smart Eye.
Svag omsättning Nettoomsättningen sjönk med 10,7% y/y under det säsongsmässigt svaga tredje kvartale...
Fortsatt pressat NAV NAV i kvartalet uppgick till 318 kr, vilket motsvarar en nedgång om 55% y/y och...
Q3-rapporten visar var skåpet ska stå Efter en aningen blek utveckling under Q2’23, så blev det leve...
Redeye comments on yesterday’s news regarding RLS’ terminated collaboration agreement with Convatec.
Kraftigt resultatlyft drivet av en rekordstark marginal.
Redeye states that reported Q3 numbers were somewhat better than we expected, with sales and earning...
Redeye provides a research update following the Q3 report published by Initiator Pharma earlier toda...
Sales SEK 17.7m, -13% vs. ABGSCe SEK 20.5m EBITDA SEK -1.
Redeye comments on Infracom's Q3 2023 report which deviated somewhat on net sales but better profita...
Redeye comments on Modelon's Q3 2023 report, which was in line on the ARR side while slightly lower ...
Redeye provides a comment on the outcome in Scandinavian ChemoTech’s rights issue.
Redeye comments on Maximum Entertainment ahead of its Q3-results (due 15 November) where we expect a...
Redeye lowers its expectations on profitability for the coming quarters following a report that mis...
Group net sales were EUR 31.4m in Q3 (Refinitiv consensus EUR 34m) meanwhile Q3 adjusted EBITDA was ...
